Drug Trial Radar · NCT05933057
Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
138
Planned (sponsor's estimate)
Start
Feb 19, 2024
Primary completion
Feb 2028
Study completion Feb 2028
Sponsor
- Lead sponsor
- ItalfarmacoIndustry
- Sponsor type
- Industry
- Collaborators
- Fortrea
- First posted
- Jul 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 9 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant male paediatric (aged 9 to \<18 years) patients with DMD. 138 patients will be randomised 2:1 to givinostat or placebo and will be treated for 18 months. * Planned screening duration: approximately 4 weeks (±14 days) * Planned treatment duration: 18 months (approximately 72 weeks) * Planned follow-up duration: 4 weeks (±7 days) (for patients not participating in the long-term safety study) * Total duration of study participation: up to 83 weeks (ie, 20-21 months)
Conditions
- Duchenne Muscular Dystrophy
Interventions
GivinostatDrug
Givinostat has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
PlaceboDrug
Placebo, manufactured to mimic givinostat, has to be administered twice daily in a fed state according to a flexible dose regimen based on patient weight. Starting dose could be reduced based on predefined safety rules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of Performance of Upper Limb 2.0 (PUL) total score at 18 months of treatment of givinostat compared to placebo group.Time frame: Baseline and 18 months
Locations
29 sites in 12 countries. Site status is shown where the registry gives one.
Universitaire Ziekenhuizen Leuven
Leuven, Belgium · Recruiting
British Columbia Children's Hospital
Vancouver, British Columbia, Canada · Recruiting
The University of Western Ontario - Children's Health Research Institute
London, Ontario, Canada · Recruiting
University of Ottawa - Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada · Recruiting
University of Toronto - Holland Bloorview Kids Rehabilitation Hospital
Toronto, Ontario, Canada · Recruiting
Klinika dětské neurologie 2. LF, Fakultní nemocnice v Motole
Prague, Czechia · Not yet recruiting
Centre Hospitalier Régional Universitaire de Lille
Lille, France · Recruiting
Centre hospitalier universitaire - Hôpitaux de Marseille
Marseille, France · Recruiting
Hôpital Armand-Trousseau - I-Motion
Paris, France · Recruiting
Charite-Universitaetsmedizin Berlin
Berlin, Germany · Recruiting
Universitätsklinikum Essen Kinder-und Jugendmedizin Neuropadiatrie
Essen, Germany · Not yet recruiting
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany · Recruiting
Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Kinder- und Jugendmedizin
Hamburg, Germany · Not yet recruiting
Associazione La Nostra Famiglia - IRCCS Eugenio Medea - Bosisio Parini
Lecco, Italy · Recruiting
Fondazione Serena Onlus - Azienda Ospedaliera Niguarda Ca' Granda - NeuroMuscular Omnicentre
Milan, Italy · Recruiting
Università degli Studi di Padova - Azienda Ospedaliera di Padova
Padova, Italy · Recruiting
Ospedale Pediatrico Bambino Gesù
Roma, Italy · Recruiting
Policlinico Universitario Agostino Gemelli - Università Cattolica del Sacro Cuore
Roma, Italy · Recruiting
Leids Universitair Medisch Centrum (LUMC)
Leiden, Netherlands · Recruiting
Radboud Universitair Medisch Centrum (Radboudumc)
Nijmegen, Netherlands · Recruiting
Uniwersyteckie Centrum Kliniczne, Klinika Neurologii Rozwojowej
Gdansk, Poland · Not yet recruiting
Uniwersyteckie Centrum Kliniczne WUM, Centralny Szpital Kliniczny
Warsaw, Poland · Not yet recruiting
Clinic of Neurology and Psychiatry for Children and Youth
Belgrade, Serbia · Not yet recruiting
Hospital Sant Joan de Déu
Barcelona, Spain · Recruiting
Hospital Universitario y Politécnico La Fe
Valencia, Spain · Recruiting
Karolinska University Hospital, Solna CKB Centrum för Kliniska Barnstudier
Stockholm, Sweden · Not yet recruiting
Newcastle upon Tyne Hospitals NHS Foundation Trust - Newcastle University
Newcastle upon Tyne, England, United Kingdom · Active not recruiting
Oxford University Hospitals NHS Foundation Trust
Oxford, England, United Kingdom · Withdrawn
NHS Greater Glasgow and Clyde - Royal Hospital for Children
Glasgow, Scotland, United Kingdom · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.